The BMPR1A Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, designed for loss-of-function studies of the bone morphogenetic protein type I receptor BMPR1A. This product features a heterogeneous pool of edited cells with targeted disruption of the BMPR1A gene, providing a versatile model for investigating BMP signaling without the need for clonal selection. The polyclonal format enables bulk analysis of pathway inhibition while preserving cellular diversity representative of the original line.
The A-549 cell line originates from human lung adenocarcinoma and is widely employed as an in vitro model of type II pneumocytes. These epithelial cells retain key features of alveolar epithelium and are extensively characterized for studies of lung cancer biology, epithelial-mesenchymal transition (EMT), and respiratory cell function. Their robust growth and well-documented genetic background make them an ideal host for CRISPR/Cas9-mediated gene disruption, facilitating the dissection of signaling networks relevant to lung adenocarcinoma and other pulmonary pathologies.
BMPR1A encodes a serine/threonine kinase receptor of the TGF-beta superfamily that is activated by BMP ligands including BMP2, BMP4, BMP6, and BMP7, and is negatively regulated by the antagonist noggin. Upon ligand binding, BMPR1A forms a heteromeric complex with the type II receptor BMPR2 and phosphorylates the receptor-regulated SMADs SMAD1, SMAD5, and SMAD8. These phosphorylated SMADs associate with the common mediator SMAD4 and the adapter protein SARA to translocate into the nucleus, where they regulate the transcription of target genes such as the inhibitor of differentiation family members ID1, ID2, and ID3. This pathway controls cell proliferation, differentiation, and EMT, highlighting BMPR1A as a pivotal upstream activator of SMAD-dependent transcriptional programs.
In the A-549 lung adenocarcinoma context, disruption of BMPR1A abolishes BMP-mediated SMAD1/5/8 phosphorylation, thereby enabling dissection of canonical and non-canonical signaling effects. Given that BMP signaling can exhibit dual tumor-suppressive or oncogenic roles, this polyclonal knockout model is instrumental in examining the receptor’s contribution to proliferation, motility, and EMT under varying conditions. Moreover, BMPR1A loss is relevant to pulmonary arterial hypertension and juvenile polyposis syndrome, extending the model’s utility to broader TGF-beta superfamily-related research beyond oncology.
These polyclonal BMPR1A knockout A-549 cells are suitable for a wide array of functional assays, including Western blotting to verify loss of BMPR1A and reduced phospho-SMAD1/5/8 levels, RT-qPCR for ID1/ID2/ID3 expression changes, and MTT assays for proliferation. Wound healing and transwell invasion assays can assess EMT and migration, while colony formation assays evaluate clonogenic growth. The model supports preclinical studies on lung adenocarcinoma, drug response modulation, and identification of BMP pathway-specific therapeutic targets. For additional information or to discuss custom gene-edited cell solutions, please contact Ascent Research.
